Author(s): Citri A, Yarden Y
Abstract Share this page
Abstract Signalling through the ERBB/HER receptors is intricately involved in human cancer and already serves as a target for several cancer drugs. Because of its inherent complexity, it is useful to envision ERBB signalling as a bow-tie-configured, evolvable network, which shares modularity, redundancy and control circuits with robust biological and engineered systems. Because network fragility is an inevitable trade-off of robustness, systems-level understanding is expected to generate therapeutic opportunities to intercept aberrant network activation.
This article was published in Nat Rev Mol Cell Biol
and referenced in Journal of Carcinogenesis & Mutagenesis